Cargando…
Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease
Vascular metabolic dysfunction presents in various diseases, such as atherosclerosis, hypertension, and diabetes mellitus. Due to the high prevalence of these diseases, it is important to explore treatment strategies to protect vascular function. Resveratrol (RSV), a natural polyphenolic phytochemic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658204/ https://www.ncbi.nlm.nih.gov/pubmed/36364370 http://dx.doi.org/10.3390/molecules27217524 |
_version_ | 1784829893024940032 |
---|---|
author | Fan, Dongxiao Liu, Chenshu Zhang, Zhongyu Huang, Kan Wang, Tengyao Chen, Sifan Li, Zilun |
author_facet | Fan, Dongxiao Liu, Chenshu Zhang, Zhongyu Huang, Kan Wang, Tengyao Chen, Sifan Li, Zilun |
author_sort | Fan, Dongxiao |
collection | PubMed |
description | Vascular metabolic dysfunction presents in various diseases, such as atherosclerosis, hypertension, and diabetes mellitus. Due to the high prevalence of these diseases, it is important to explore treatment strategies to protect vascular function. Resveratrol (RSV), a natural polyphenolic phytochemical, is regarded as an agent to regulate metabolic pathways. Many studies have proven that RSV has beneficial effects on improving metabolism in endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), which provide new directions to treat vascular metabolic diseases. Herein, we overviewed that RSV could regulate cell metabolism activity by inhibiting glucose uptake, suppressing glycolysis, preventing cells from fatty acid-related damages, reducing lipogenesis, increasing fatty acid oxidation, enhancing lipolysis, elevating uptake and synthesis of glutamine, and increasing NO release. Furthermore, in clinical trials, although the results from different studies remain controversial, we proposed that RSV had better therapeutic effects at high concentrations and for patients with metabolic disorders. |
format | Online Article Text |
id | pubmed-9658204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96582042022-11-15 Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease Fan, Dongxiao Liu, Chenshu Zhang, Zhongyu Huang, Kan Wang, Tengyao Chen, Sifan Li, Zilun Molecules Review Vascular metabolic dysfunction presents in various diseases, such as atherosclerosis, hypertension, and diabetes mellitus. Due to the high prevalence of these diseases, it is important to explore treatment strategies to protect vascular function. Resveratrol (RSV), a natural polyphenolic phytochemical, is regarded as an agent to regulate metabolic pathways. Many studies have proven that RSV has beneficial effects on improving metabolism in endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), which provide new directions to treat vascular metabolic diseases. Herein, we overviewed that RSV could regulate cell metabolism activity by inhibiting glucose uptake, suppressing glycolysis, preventing cells from fatty acid-related damages, reducing lipogenesis, increasing fatty acid oxidation, enhancing lipolysis, elevating uptake and synthesis of glutamine, and increasing NO release. Furthermore, in clinical trials, although the results from different studies remain controversial, we proposed that RSV had better therapeutic effects at high concentrations and for patients with metabolic disorders. MDPI 2022-11-03 /pmc/articles/PMC9658204/ /pubmed/36364370 http://dx.doi.org/10.3390/molecules27217524 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Fan, Dongxiao Liu, Chenshu Zhang, Zhongyu Huang, Kan Wang, Tengyao Chen, Sifan Li, Zilun Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease |
title | Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease |
title_full | Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease |
title_fullStr | Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease |
title_full_unstemmed | Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease |
title_short | Progress in the Preclinical and Clinical Study of Resveratrol for Vascular Metabolic Disease |
title_sort | progress in the preclinical and clinical study of resveratrol for vascular metabolic disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658204/ https://www.ncbi.nlm.nih.gov/pubmed/36364370 http://dx.doi.org/10.3390/molecules27217524 |
work_keys_str_mv | AT fandongxiao progressinthepreclinicalandclinicalstudyofresveratrolforvascularmetabolicdisease AT liuchenshu progressinthepreclinicalandclinicalstudyofresveratrolforvascularmetabolicdisease AT zhangzhongyu progressinthepreclinicalandclinicalstudyofresveratrolforvascularmetabolicdisease AT huangkan progressinthepreclinicalandclinicalstudyofresveratrolforvascularmetabolicdisease AT wangtengyao progressinthepreclinicalandclinicalstudyofresveratrolforvascularmetabolicdisease AT chensifan progressinthepreclinicalandclinicalstudyofresveratrolforvascularmetabolicdisease AT lizilun progressinthepreclinicalandclinicalstudyofresveratrolforvascularmetabolicdisease |